Antidepressant medications and osteoporosis

Use of antidepressant medications that act on the serotonin system has been linked to detrimental impacts on bone mineral density (BMD), and to osteoporosis. This article reviews current evidence for such effects, and identifies themes for future research. Serotonin receptors are found in all major...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Rizzoli, R, Cooper, C, Reginster, J, Abrahamsen, B, Adachi, J, Brandi, M, Bruyère, O, Compston, J, Ducy, P, Ferrari, S, Harvey, N, Kanis, J, Karsenty, G, Laslop, A, Rabenda, V, Vestergaard, P
Materialtyp: Journal article
Publicerad: 2012
_version_ 1826300424680898560
author Rizzoli, R
Cooper, C
Cooper, C
Reginster, J
Abrahamsen, B
Adachi, J
Brandi, M
Bruyère, O
Compston, J
Ducy, P
Ferrari, S
Harvey, N
Kanis, J
Karsenty, G
Laslop, A
Rabenda, V
Vestergaard, P
author_facet Rizzoli, R
Cooper, C
Cooper, C
Reginster, J
Abrahamsen, B
Adachi, J
Brandi, M
Bruyère, O
Compston, J
Ducy, P
Ferrari, S
Harvey, N
Kanis, J
Karsenty, G
Laslop, A
Rabenda, V
Vestergaard, P
author_sort Rizzoli, R
collection OXFORD
description Use of antidepressant medications that act on the serotonin system has been linked to detrimental impacts on bone mineral density (BMD), and to osteoporosis. This article reviews current evidence for such effects, and identifies themes for future research. Serotonin receptors are found in all major types of bone cell (osteoblasts, osteocytes, and osteoclasts), indicating an important role of the neuroendocrine system in bone. Observational studies indicate a complex relationship between depression, antidepressants, and fracture. First, the presence of depression itself increases fracture risk, in relation with decreased BMD and an increase in falls. A range of aspects of depression may operate, including behavioral factors (e.g., smoking and nutrition), biological changes, and confounders (e.g., comorbidities and concomitant medications). A substantial proportion of depressed patients receive antidepressants, mostly selective serotonin reuptake inhibitors (SSRIs). Some of these have been linked to decreased BMD (SSRIs) and increased fracture risk (SSRIs and tricyclic agents). Current use of SSRIs and tricyclics increases fracture risk by as much as twofold versus nonusers, even after adjustment for potential confounders. While there is a dose-response relationship for SSRIs, the effect does not appear to be homogeneous across the whole class of drugs and may be linked to affinity for the serotonin transporter system. The increase in risk is the greatest in the early stages of treatment, with a dramatic increase after initiation, reaching a peak within 1. month for tricyclics and 8. months for SSRIs. Treatment-associated increased risk diminishes towards baseline in the year following discontinuation. The body of evidence suggests that SSRIs should be considered in the list of medications that are risk factors for osteoporotic fractures. © 2012 Elsevier Inc.
first_indexed 2024-03-07T05:16:58Z
format Journal article
id oxford-uuid:dd899f28-94e5-4a5b-99e8-b7ac26f3b448
institution University of Oxford
last_indexed 2024-03-07T05:16:58Z
publishDate 2012
record_format dspace
spelling oxford-uuid:dd899f28-94e5-4a5b-99e8-b7ac26f3b4482022-03-27T09:25:48ZAntidepressant medications and osteoporosisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:dd899f28-94e5-4a5b-99e8-b7ac26f3b448Symplectic Elements at Oxford2012Rizzoli, RCooper, CCooper, CReginster, JAbrahamsen, BAdachi, JBrandi, MBruyère, OCompston, JDucy, PFerrari, SHarvey, NKanis, JKarsenty, GLaslop, ARabenda, VVestergaard, PUse of antidepressant medications that act on the serotonin system has been linked to detrimental impacts on bone mineral density (BMD), and to osteoporosis. This article reviews current evidence for such effects, and identifies themes for future research. Serotonin receptors are found in all major types of bone cell (osteoblasts, osteocytes, and osteoclasts), indicating an important role of the neuroendocrine system in bone. Observational studies indicate a complex relationship between depression, antidepressants, and fracture. First, the presence of depression itself increases fracture risk, in relation with decreased BMD and an increase in falls. A range of aspects of depression may operate, including behavioral factors (e.g., smoking and nutrition), biological changes, and confounders (e.g., comorbidities and concomitant medications). A substantial proportion of depressed patients receive antidepressants, mostly selective serotonin reuptake inhibitors (SSRIs). Some of these have been linked to decreased BMD (SSRIs) and increased fracture risk (SSRIs and tricyclic agents). Current use of SSRIs and tricyclics increases fracture risk by as much as twofold versus nonusers, even after adjustment for potential confounders. While there is a dose-response relationship for SSRIs, the effect does not appear to be homogeneous across the whole class of drugs and may be linked to affinity for the serotonin transporter system. The increase in risk is the greatest in the early stages of treatment, with a dramatic increase after initiation, reaching a peak within 1. month for tricyclics and 8. months for SSRIs. Treatment-associated increased risk diminishes towards baseline in the year following discontinuation. The body of evidence suggests that SSRIs should be considered in the list of medications that are risk factors for osteoporotic fractures. © 2012 Elsevier Inc.
spellingShingle Rizzoli, R
Cooper, C
Cooper, C
Reginster, J
Abrahamsen, B
Adachi, J
Brandi, M
Bruyère, O
Compston, J
Ducy, P
Ferrari, S
Harvey, N
Kanis, J
Karsenty, G
Laslop, A
Rabenda, V
Vestergaard, P
Antidepressant medications and osteoporosis
title Antidepressant medications and osteoporosis
title_full Antidepressant medications and osteoporosis
title_fullStr Antidepressant medications and osteoporosis
title_full_unstemmed Antidepressant medications and osteoporosis
title_short Antidepressant medications and osteoporosis
title_sort antidepressant medications and osteoporosis
work_keys_str_mv AT rizzolir antidepressantmedicationsandosteoporosis
AT cooperc antidepressantmedicationsandosteoporosis
AT cooperc antidepressantmedicationsandosteoporosis
AT reginsterj antidepressantmedicationsandosteoporosis
AT abrahamsenb antidepressantmedicationsandosteoporosis
AT adachij antidepressantmedicationsandosteoporosis
AT brandim antidepressantmedicationsandosteoporosis
AT bruyereo antidepressantmedicationsandosteoporosis
AT compstonj antidepressantmedicationsandosteoporosis
AT ducyp antidepressantmedicationsandosteoporosis
AT ferraris antidepressantmedicationsandosteoporosis
AT harveyn antidepressantmedicationsandosteoporosis
AT kanisj antidepressantmedicationsandosteoporosis
AT karsentyg antidepressantmedicationsandosteoporosis
AT laslopa antidepressantmedicationsandosteoporosis
AT rabendav antidepressantmedicationsandosteoporosis
AT vestergaardp antidepressantmedicationsandosteoporosis